PMID- 17503347
OWN - NLM
STAT- MEDLINE
DCOM- 20070531
LR  - 20211203
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 22
IP  - 8
DP  - 2007 Aug
TI  - Mammalian target of rapamycin: master regulator of cell growth in the nervous 
      system.
PG  - 895-903
LID - 10.14670/HH-22.895 [doi]
AB  - The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine 
      protein kinase that regulates a number of diverse biologic processes important 
      for cell growth and proliferation, including ribosomal biogenesis and protein 
      translation. In this regard, hyperactivation of the mTOR signaling pathway has 
      been demonstrated in numerous human cancers, including a number of inherited 
      cancer syndromes in which individuals have an increased risk of developing benign 
      and malignant tumors. Three of these inherited cancer syndromes (Lhermitte-Duclos 
      disease, neurofibromatosis type 1, and tuberous sclerosis complex) are 
      characterized by significant central nervous system dysfunction and brain tumor 
      formation. Each of these disorders is caused by a genetic mutation that disrupts 
      the expression of proteins which negatively regulate mTOR signaling, indicating 
      that the mTOR signaling pathway is critical for appropriate brain development and 
      function. In this review, we discuss our current understanding of the mTOR 
      signaling pathway and its role in promoting ribosome biogenesis and cell growth. 
      We suggest that studies of this pathway may prove useful in identifying molecular 
      targets for biologically-based therapies of brain tumors associated with these 
      inherited cancer syndromes as well as sporadic central nervous system tumors.
FAU - Sandsmark, D K
AU  - Sandsmark DK
AD  - Department of Neurology, Washington University School of Medicine, St. Louis, MO 
      63110, USA.
FAU - Pelletier, C
AU  - Pelletier C
FAU - Weber, J D
AU  - Weber JD
FAU - Gutmann, D H
AU  - Gutmann DH
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/pharmacology/therapeutic use
MH  - Brain Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - *Cell Proliferation/drug effects
MH  - Central Nervous System/drug effects/*metabolism/pathology
MH  - Humans
MH  - Mutation
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Protein Kinases/genetics/*metabolism
MH  - Ribosomes/metabolism
MH  - *Signal Transduction/drug effects
MH  - Sirolimus/pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases
RF  - 84
EDAT- 2007/05/16 09:00
MHDA- 2007/06/01 09:00
CRDT- 2007/05/16 09:00
PHST- 2007/05/16 09:00 [pubmed]
PHST- 2007/06/01 09:00 [medline]
PHST- 2007/05/16 09:00 [entrez]
AID - 10.14670/HH-22.895 [doi]
PST - ppublish
SO  - Histol Histopathol. 2007 Aug;22(8):895-903. doi: 10.14670/HH-22.895.